Gary, the possibility that BP could make our treatment disappear by buying it and never developing it is one of the major reasons NWBO has chosen to go it alone, rather than sell. This is also why I think they may partner, but not sell, at least initially. NWBO has spent a lot of time developing the path to commercialization of their DCVax products. I don’t see them giving up complete control until they have the product commercialized and in the public eye. Then BP cannot lock it away in a closet and continue with relatively useless, but momentarily lucrative, cancer drugs. It’s also a good reason for holding out for a high price. When they ultimately sell, if they ever do, the price should be high enough that only commercializing DCVax will make fiscally responsible sense.